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Your sleep cycles ebb and flow, governed
by hormones and light, just as tides are
pulled by the moon. But the artificial
rhythms of our society, including shift
work and air travel across time zones, are
not conducive to rest. A third of Americans
suffer from sleeplessness, according to
theNIH.Becausescreening anddiagnosis
is not uniform, prevalence is uncertain. At
least 30 million Americans are estimated
to experience insomnia, but the number
could be much higher. It is unclear how
many are chronic insomniacs.
There are dozens of sleep disorders,
but insomnia, sleep apnea, and circadian
rhythm disorders are the most common.
Most insomnia is transitory, caused by
stress. Sleep disturbance can also be trig-
gered by alcohol, caffeine, cigarette
smoking, and certain prescription drugs.
Most commonly, insomnia is comorbid
with other conditions such as depression,
anxiety, ADHD in children, dementia, and
various physical problems, including dia-
betes (NIH State-of-the-Science State-
ment on Manifestations andManagement
of Chronic Insomnia in Adults, http://
consensus.nih.gov/2005/2005Insomnia
SOS026html.htm).
According to Joyce Walsleben, Ph.D.,
associate professor of medicine at the
NYU Langone Medical Center, insomnia
is commonly treated by drugs and behav-
ioral therapies. People experiencing
transient insomnia will try to self-medicate
with alcohol or antihistamines or will men-
tion it to a general practitioner, who, strap-
ped for time, will prescribe a sleep drug. If
they go to a sleep specialist, it is typically
to get off the medication. They will prob-
ably be offered a mixed course of drugs,
short-term, and then behavioral therapy.
New drugs in development like Acte-
lion’s Almorexant are not intended to put
you to sleep, but rather to keep you from
waking and to prevent grogginess. They
are targeted at a potentially large market.
Windhover Information, Inc., values the
worldwide insomnia market as worth
$4.6 billion: $3.5 billion in the U.S., $700
million in Europe, and $460 million in
Japan.
Valley of the Dolls
Readers of a certain vintage may recall
‘‘Valley of the Dolls,’’ Jacqueline Susann’s
1966 bestseller about starlets, sex, and
drugs. ‘‘Dolls’’ were tranquilizers. Satiri-
cally immortalized in ‘‘Mother’s Little
Helper’’ by the Rolling Stones, benzodiaz-
epine receptor agonists were prescribed
for stress in the 1960s and 1970s. These
sedatives enhanced the effects of
gamma-aminobutyric acid (GABA) an
inhibitory neurotransmitter in the central
nervous system. However, they led to
cognitive problems and addiction.
Several next-generation sedative-
hypnotics, called nonbenzodiazepines,
informally known as ‘‘Z’’ drugs, include
zolpidem, now generic (marketed as Am-
bien by Sanofi Aventis); zolpidem CR; za-
leplon, now generic (marketed as Sonata
by King Pharmaceuticals); and eszopli-
clone (Sepracor’s Lunesta, the only drug
of this category approved for long-term
use). As they selectively bind to the
GABAA receptor, they produce fewer
side effects but still can cause depen-
dence. In 2007, the FDA instituted
stronger labeling for these sedative-
hypnotics, as people who took them
occasionally experienced anaphylaxis
and swelling as well as made phone calls,
raided the refrigerator, and drove while
asleep with no memory of doing so.
Takeda Pharmaceuticals’ Ramelteon
(marketed as Rozerem) melatonin
receptor agonist, which targets receptors
that regulate the circadian sleep-wake
cycle, is approved by the FDA for long-
term use. Ramelteon selectively binds to
the MT1 and MT2 receptors in the supra-
chiasmatic nucleus (SCN) instead of
GABA A receptors, as do the Z drugs,
hopefully bypassing side effects.
Other medications, such as antidepres-
sants and antipsychotics, are prescribed
off-label for insomnia. Over- the-counter
drugs include antihistamines, melatonin,
valerian, and L-tryptophan, all which
have uncertain effectiveness.
Terra Incognita inside Your Head
Researchers can monitor the successive
phases of rapid eye movement (REM),
when dreaming and memory consolida-
tion is believed to take place, and the
four stages of non-REM sleep (NREM).
But nobody really knows why we sleep.
Sleep seems to restore body and mind,
consolidate memories, and reinforce
learning. It may nurture brain plasticity.
The need for sleep varies between individ-
uals. Humans sleep between 7 and 9 hr in
a 24 hr cycle. Sleep patterns and quality
change throughoutone’s lifetime.Unfortu-
nately, quality of sleep is hard to measure.
While insomnia is synonymous with
misery and in the short-term can impair
mental function and memory, its long-
term effects are unclear. In one experi-
ment, rats deprived of sleep died within
weeks. But unlike rats, people don’t die
of sleeplessness, except for a few who
suffer from a rare genetic condition called
fatal familial sleep disorder.
‘‘I think the more pressing question is
that the drugs have side effects,’’ said
Dr. Jerome Siegel, director of the Sleep
Research Center at UCLA. ‘‘I am not
aware of any evidence that sleeping pills
have a health benefit.’’ According to
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affect daytime function.
Studies show that fatigue from sleep
deprivation in shift work can lead to
mistakes and accidents, as well. Shift
workers also can experience greater rates
of irritability and depression and report
increased gastrointestinal and cardiovas-
cular disorders. (Scott, 2000).
Siegel refers to a study of over 1.1
million subjects commissioned by the
American Cancer Society (Kripke et al.,
2002) which showed that chronic users
of hypnotics had shortened lifespans,
whereas people with untreated insomnia
didn’t. However, sleep time was not
directly related to lifespan. More than
one epidemiological study shows that
across a population, sleepers are on a U-
shaped curve. People who get too much
sleep or people lacking sleep tend to die
quicker, but, Siegel says, those with
increased sleep are actually at greater
risk than those with decreased sleep.
As sleep is governed by hormones, lack
of sleep or poor quality sleep is increas-
ingly correlated to heart disease, diabetes,
and obesity. Professor Eve Van Cauter, at
the Department of Medicine at the Univer-
sity of Chicago, managed to turn a group
of young people into the equivalent of dia-
betics by depriving them of sleep for
a week (Knutson and Van Cauter, 2008).
However, these studies on health
effects were done on normal people,
says James Walsh, Ph.D, director of the
Sleep Medical Center, St Luke’s Hospital,
and scientific board member of Somnus
Therapeutics, a sleep drug startup. Few
studies have been done on insomniacs.
New Hope for Night Owls
Research into the brain’s reward system
paved the way for Swiss company
Actelion’s (http://www.actelion.com)
compound Almorexant (ACT078573), an
orexin receptor antagonist. Almorexant
doesn’t put you to sleep, but it keeps
you from waking up prematurely.
Actelion, incorporated in 1997, is
public. The company is also engaged in
developing new chemical entities and
compounds based on ion channels, as-
partic proteinases, and GPCRs. Actelion
is also in the enviable position of having
a billion dollars of cash in the bank.
Orexins (or hypocretins) are neuropep-
tide modulators produced by the brain
that direct wakefulness and reward106 Chemistry & Biology 16, February 27, 20seeking behavior. ‘‘The existing drugs
induce your brain not to work, [causing]
anesthesia.’’ says Actelion’s CEO, Jean-
Paul Clozel. ‘‘They decrease the function
of the brain. You use your night to make
order in the brain. Orexin prevents you
from waking up. If you wake up, you go
back to sleep normally. You are dreaming
normally.’’
In a collaboration with GlaxoSmithKline
that started in 2008, Almorexant entered
RESTORA 1 (REstore normal physiological
Sleepwith TheOrexinReceptor antagonist
Almorexant), a phase III study comparing it
to Ambien. So far, according to Clozel,
studysubjectshavenotdemonstratedclin-
ical ill effects or next-day impairment in
motor skills and reaction time.
Not Letting Sleeping Dogs Lie
Thehypocretin/orexinpeptidesand recep-
tors were discovered in 1998 by two
groups independently: one led by Luis de
Lecea, Ph.D., at Stanford, who called
them hypocretins (HCRT) to show they
are a hypothalamic member of the incretin
family; andanother, headedbyDr. Takeshi
Sakurai at the University of Tsukuba,
Japan, who named them orexins, as they
help regulate feeding behavior.
‘‘The first experiments were oriented
towards obesity, but it was clear it wasn’t
the main function,’’ said de Lecea. ‘‘The
peptide functions in arousal, brain reward,
and goal seeking behaviors.’’ According
to de Lecea, there are two different hypo-
cretin receptors. The mutation in receptor
2 results in narcolepsy in dogs and has
arousal functions. The functions of
receptor 1 are still unknown. Human and
canine narcolepsy is the same disease,
resulting from a malfunction of HCRT,
but narcolepsy is genetic in dogs and
probably an immune malfunction in
humans. Both receptors are widespread
throughout the brain as well as in other
tissues. ‘‘Obviously, the compound of
Actelion is a nonselective inhibitor of
both receptors,’’ de Lecea said. ‘‘It might
affect both arousal and behavior.’’
Second Acts for Old Drugs
In sleep drugs, dose matters. San Diego-
based Somaxon (http://www.somaxon.
com) is reformulating doxepin, a generic
antidepressant and selective H1 antago-
nist, betting that in low doses it will not
produce the side effects associated with
higher doses of the drug. Dr. Neil Kavey,09 ª2009 Elsevier Ltd All rights reserveda psychiatrist at Columbia Presbyterian
Medical Center, noticed his patients who
took doxepin slept through the night,
and prescribed it off-label for insomnia.
The company, founded in 2003, is
public. Silenor, a low-dose (1–6 mg)
formulation of doxepin for patients with
chronic insomnia, is currently awaiting
FDA approval. The company has con-
ducted four randomized, placebo-
controlled phase III trials on groups with
transient and chronic insomnia, ranging
from 229 to 565 people, to measure
effects including sleep onset, sleep main-
tenance, early morning awakenings, and
residual effects.
New Jersey startup Somnus (http://
www.somnusthera.com) is taking advan-
tage of zaleplon’s short half-life, reformu-
lating it for timed release. According to
James Walsh, tinkering with the half-life
of a generic drug with an established
safety profile to turn it into a sleep mainte-
nance drug is hypothetically attractive.
The company is attempting to calibrate
the drug to kick in after the first few hours
of natural sleep, but as Walsh points out,
there is variability inhowpeoplemetabolize
drugs. The rejiggered drug still is regarded
as potentially addictive. Somnus’ French
scientific collaborator will shortly begin
testing patients on driving simulators to
check for residual effects on coordination.
But can the quick-fix these drugs
promise bemore effective than behavioral
methods? A 6 week course in cognitive
behavior therapy (CBT) achieves impres-
sive results that are still evident 6 months
out, but the effects of a pill cease when
you stop taking it. According to Walsh, it
is often a matter of patient and doctor
preference, but skilled CBT practitioners
are scarce, and while insurance compa-
nies may not pay for a psychologist, they
will pay for drugs.
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